病因分层单细胞图谱识别FABP4作为MASLD相关HCC预后标志物
本研究对12例HCC患者肿瘤及癌旁组织行单细胞RNA测序,比较HBV和MASLD不同病因组合的肿瘤微环境,发现HBV+MASLD+ HCC免疫治疗后预后最佳,FABP4在MASLD相关HCC肿瘤内皮细胞高表达并促进血管正常化和CD8+ T细胞浸润,高表达与更好预后相关。
要点
- HBV+MASLD+ HCC患者免疫治疗后预后最佳。
- MASLD+ HCC中CD8+ T细胞浸润增加、巨噬细胞减少。
- FABP4高表达与更好预后相关,或可指导免疫治疗。
核心结论
- HCC存在病因异质性免疫景观,FABP4是MASLD相关HCC潜在预后标志物。
研究设计与样本
- 对12例HCC患者配对肿瘤和癌旁组织行单细胞RNA测序。
- 分析TCGA-LIHC和两个免疫治疗HCC队列的bulk RNA测序数据。
- 验证包括224例样本免疫组化、多重免疫组化及体内外实验。
主要发现
- HBV+MASLD+ HCC免疫治疗后预后最佳。
- MASLD+ HCC较MASLD- HCC的CD8+ T细胞浸润增加、巨噬细胞丰度降低。
- HBV+ HCC的肿瘤反应性T细胞评分和M1样巨噬细胞特征显著高于HBV-病例。
- HBV+MASLD+ HCC中前体耗竭CD8+ T细胞比例更高。
- FABP4在MASLD相关HCC肿瘤内皮细胞高表达,受PPARγ调控,促进血管正常化和CD8+ T细胞浸润。
关键数值与推荐
- FABP4高表达与更好预后相关。
- BMS309403抑制FABP4会削弱抗PD-1疗效并减弱血管正常化和细胞毒性CD8+ T细胞浸润。
临床怎么用
- FABP4高表达或可作为MASLD相关HCC免疫治疗获益的预后标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The impact of HBV infection and metabolic dysfunction-associated steatotic liver disease (MASLD) on the tumor microenvironment in hepatocellular carcinoma (HCC) remains unclear. The aim of this study was to compare the tumor microenvironment among HBV-MASLD-, HBV-MASLD+, HBV+MASLD-, HBV+MASLD+ HCC, and to identify etiology-specific prognostic biomarkers. METHODS: Single-cell RNA-sequencing was performed on paired tumor and adjacent tissues from 12 patients with HCC. Bulk RNA-sequencing data from the TCGA-LIHC and two immunotherapy-treated HCC cohorts were analyzed to assess FABP4's role in vascular normalization and prognosis. Validation included immunohistochemistry on 224 samples, multiplex immunohistochemistry, in vitro and in vivo experiments. RESULTS: We compared the prognosis of patients with different etiologies of HCC and found that those with HBV+MASLD+ HCC exhibited the most favorable outcome following immunotherapy. Compared to MASLD- HCC, MASLD+ HCC showed increased infiltration of CD8+ T cells and reduced macrophage abundance. In HBV+ HCC, tumor-reactive and tumor-specific T-cell scores, and M1-like macrophage signatures were significantly higher than in HBV- cases. HBV+MASLD+ HCC also featured a higher proportion of precursor-exhausted CD8+ T cells. Additionally, FABP4 was predominantly expressed in tumor endothelial cells in MASLD-related HCC, regulated by PPARγ. FABP4 facilitated vascular normalization and enhanced CD8+ T-cell infiltration. Mechanistically, FABP4 overexpression upregulated multiple vascular-stabilizing genes and downregulated destabilizing genes, associated with Notch1 pathway activation. Inhibition of FABP4 using BMS309403 impaired anti-PD-1 efficacy and attenuated vascular normalization and cytotoxic CD8+ T-cell infiltration in MASLD-related HCC mouse models. Clinically, high FABP4 expression correlated with better prognosis. CONCLUSIONS: These findings reveal etiology-heterogeneous immune landscapes in HCC and identify FABP4 as a potential prognostic biomarker to guide immunotherapy in MASLD-related HCC. IMPACT AND IMPLICATIONS: This study systematically analyzed the impact of HBV, metabolic dysfunction-associated steatotic liver disease (MASLD), and their coexistence on responses to immunotherapy and outcomes in hepatocellular carcinoma (HCC). By integrating single-cell sequencing of patient samples, it highlights the importance of etiological heterogeneity, particularly from the perspective of CD8+ T cells. The study identifies FABP4 as being highly expressed in MASLD-related HCC and implicates it in promoting vascular normalization and CD8+ T-cell infiltration. Most importantly, FABP4 emerges as a potential prognostic biomarker for HCC, especially in MASLD-related cases, offering a practical tool to identify patients who are more likely to benefit from immunotherapy.
引用
- Zhang S, Xu H, Li M, et al. An etiology-stratified single-cell atlas identifies FABP4 as a prognostic marker for MASLD-related HCC. J Hepatol. 2025. PMID: 41205757. doi:10.1016/j.jhep.2025.10.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。